REFERENCES
1. Mateos MV. How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events. Leuk Res . 2012;36 Suppl 1:S35-43. doi:10.1016/S0145-2126(12)70007-3
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer . 2007;7(8):585-598. doi:10.1038/nrc2189
3. Ogmundsdóttir HM, Haraldsdóttir V, M Jóhannesson G, et al. Monoclonal gammopathy in Iceland: a population-based registry and follow-up.Br J Haematol . 2002;118(1):166-173. doi:10.1046/j.1365-2141.2002.03589.x
4. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.Blood . 2006;107(3):904-906. doi:10.1182/blood-2005-08-3449
5. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc . 2007;82(12):1468-1473. doi:10.1016/S0025-6196(11)61089-6
6. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine . 2006;354(13):1362-1369. doi:10.1056/nejmoa054494
7. Blessum C, Jeppsson JO, Aguzzi F, Bernon H, Bienvenu J. [Capillary electrophoresis: principles and practice in clinical laboratory].Ann Biol Clin (Paris) . 1999;57(6):643-657.
8. Abdallah N, Rajkumar SV, Greipp P, et al. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal 2020 10:8 . 2020;10(8):1-9. doi:10.1038/s41408-020-00348-5
9. Decaux O, Rodon P, Ruelland A, Estepa L, Leblay R, Grosbois B. Épidémiologie descriptive des gammapathies monoclonales. Expérience d’un centre hospitalier général et d’un service de médecine interne de centre hospitalier et universitaire. Revue de Medecine Interne . 2007;28(10):670-676. doi:10.1016/j.revmed.2007.04.011
10. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clinical Chemistry . 2009;55(8):1517-1522. doi:10.1373/clinchem.2009.126664
11. Belouni R, Allam I, Cherguelaine K, et al. Epidemiological and immunochemical parameters of monoclonal plasma cell dyscrasias of 2121 cases in Algeria. Current Research in Translational Medicine . 2020;68(2):67-70. doi:10.1016/j.retram.2019.11.003
12. Mseddi-Hdiji S, Haddouk S, Ben Ayed M, et al. Gammapathies monoclonales en Tunisie: Analyse épidé miologique, immunochimique et étiologique d’une série de 288 cas. Pathologie Biologie . 2005;53(1):19-25. doi:10.1016/j.patbio.2004.01.014
13. R G, M D, L K, et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study.Clinical lymphoma, myeloma & leukemia . 2018;18(9):e345-e350. doi:10.1016/J.CLML.2018.06.005
14. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood . 2003;101(7):2496-2506. doi:10.1182/blood-2002-07-2299
15. Singh G. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies. The journal of applied laboratory medicine . 2020;5(6):1358-1371. doi:10.1093/JALM/JFAA153
16. O L, BI G, JA K, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia . 2014;28(7):1537-1542. doi:10.1038/LEU.2014.34